Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CELSION CORP. (CLN was CELN) UP $.33 TO $.59 ON HUGE NEWS -- Ignore unavailable to you. Want to Upgrade?

To: Dave Gore who wrote (230)	1/31/1999 2:38:00 PM
From: Larry Brew	Respond to of 518

Dave, I don't like the MM's actions either. They want volatility. That's where the money is. They work to move it down just like moving it up. They usually post without substance. That's a red flag for me, be it hype or verbal destruction. I can play either way, but I work to support my personal comments. You should read the posts from the beginning. My personal OPINION, and I stress opinion, is that most negative comments have come after Friday's run by posters not holding positions. Maybe, and I stress maybe, MM's looking for a nice entry to pump and dump? $1.15 isn't exactly a pumped up price for a long term investment. Little downside with great potential. I said it before and I'll say it again. It's risk / reward. If and when results blow your socks off, it's too late. If they fail, there's little loss unless you bet the farm. I bet you buy. :-) Larry

To: Dave Gore who wrote (230)	1/31/1999 3:26:00 PM
From: Robert Einstein	Read Replies (2) \| Respond to of 518

BusinessWire, Monday, November 09, 1998 at 08:45 COLUMBIA, Md.--(BUSINESS WIRE)--Nov. 9, 1998--Celsion Corp. (OTC BB:CELN) today announced that it has appointed Peter Gombrich to the board, replacing former director Mel Soule. A seasoned executive with over 30 years experience in the healthcare industry, Gombrich brings to Celsion a proven ability to create and develop successful private and publicly-held medical device companies with over $100 million in annual revenues. Two of these companies yielded a 10-fold return to original investors. "During his distinguished career in the healthcare industry, Peter Gombrich has forged strong strategic contacts with physicians, companies, and research organizations worldwide," commented Celsion President and CEO Spencer Volk. "His expertise with start-up medical device firms will be of great benefit to Celsion as we prepare to begin clinicals on our breast cancer and BPH treatment systems." In 1976 Gombrich co-founded St. Jude Medical, Inc. (NYSE:STJ), a world renowned life support medical device company that specializes in the global cardiovascular industry. As executive vice president and subsequently president of the pacemaker division, he oversaw product development as well as St. Jude Medical's corporate evolution as the world's leading heart valve company. During his five years at Medtronic, Inc. (NYSE:MDT), the world's leading medical technology company which specializes in implantable and interventional therapies, Gombrich directed Medtronic's sales and marketing efforts leading to the company's early significant growth. After founding Clinicom, Inc. in 1982, Gombrich was instrumental in developing the company as a leader in the bedside clinical information systems industry. After Clinicom was taken public it was subsequently acquired by HBO & Company (NASDAQ:HBOC), a major healthcare information systems company that delivers enterprise-wide patient care, clinical, financial, and strategic management software solutions and other services to healthcare organizations worldwide. In 1994 Gombrich founded AccuMed International, Inc. (NASDAQ:ACMI), an emerging global leader in integrated, technology-driven cytopathology and microbiology systems. As chairman, president, and chief executive officer, Gombrich oversaw AccuMed's product development and commercialization as well as its strategic alliances with worldwide enterprises. Gombrich grew AccuMed's annual revenues in excess of $20 million and left to pursue the business of InPath, LLC where he currently serves as chief executive officer and chairman. Founded by Gombrich in February 1998 based on technology and biomolecular licenses, InPath develops point-of-care diagnostic systems for cervical, gastrointestinal, and pulmonary markets. The Company has strategic alliances with numerous healthcare companies and world renowned medical professionals and scientists to conduct its research and development, clinical investigations, product design, manufacturing, and marketing. Gombrich holds a bachelor's degree in electrical engineering from the University of Denver/Colorado and a master's in business administration from the University of Denver. He also currently serves as a director for Sunquest Information Systems, Inc. (NASDAQ:SUNQ), a leader in healthcare automation since 1979 which specializes in clinical information systems and posted over $100 million in fiscal 1997 revenues. Celsion Corporation is a research and development company dedicated to commercializing medical treatment systems for cancer and benign prostatic hyperplasia using focused heat delivered by patented microwave technologies. Clinicals and further development of the Company's treatment systems are being conducted by leading institutions such as the Massachusetts Institute of Technology, Massachusetts General Hospital, Montefiore Medical Center, and Duke University in the United States, and Hammersmith Hospital and Oxford University in England. This is from november 1998!!!. Read it carefully !!!!!! . A man of this stature is "NOT" going to join some crooked outfit Robert